Read, save, and print articles from the current issue


Chronological index


Compare all instruments
and software systems


Chronological index


Register Now and
On Demand

Home » Category


From the President’s Desk: What we learn from member surveys, 5/18

May 2018—As a professional society, we want to know what our members need so we can provide services and programs to help them excel. We know that pathology practices are diverse because they have to be—science is never static. We also know that practice settings vary widely. In short, CAP members’ interests and concerns are uncommonly diverse because our field is uncommonly diverse.

Clinical Pathology Abstracts, 5/18

May 2018—Use of a smartphone app to assess neonatal jaundice: Neonates are screened for hyperbilirubinemia before hospital discharge using a transcutaneous or total serum bilirubin measurement. However, levels peak at approximately 96 hours of life, which is after most healthy infants have left the hospital. Outpatient follow-up is often performed by visual inspection, but this can be highly variable and have poor interobserver agreement.

Anatomic Pathology Abstracts, 5/18

May 2018—Outcomes related to use of hygroscopic sonographically detectable clips: The use of hygroscopic sonographically detectable clips (HSDCs) has dramatically increased in recent years, especially for breast cancer patients who undergo neoadjuvant chemotherapy. The authors conducted a study to define the appearance of HSDC sites in histopathological specimens and allow pathologists to recognize these sites and differentiate them from other lesions.

Molecular Pathology Abstracts, 5/18

May 2018—DNA methylation-based testing to classify central nervous system tumors: Despite being the mainstay of pathology tissue diagnostics, microscope-based histological review has limitations. Among them is that pathologists may have differing opinions about a case. This interobserver variability may result in over- or undertreatment of the patient and lack of agreement about which diagnosis is correct.

Newsbytes, 5/18

May 2018—Vendor neutral archives: A fit for the pathology lab? Whether the initialism VNA will become as recognizable as the acronym PACS in the pathology field remains to be seen, but pathologists and vendors alike are considering how vendor neutral archives may benefit the pathology lab.

Q&A column, 5/18

May 2018—Our immunohistochemistry laboratory is moving to a new building across the street. We are not getting new equipment, just moving the machines to the new building. Do we need to perform a full revalidation of all our antibodies?

Put It on the Board, 5/18

May 2018—FDA approves osimertinib for NSCLC, nivolumab + ipilimumab for RCC: The FDA on April 18 approved osimertinib (Tagrisso, AstraZeneca) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

From the President’s Desk: Pathologists as medicine’s first responders, 4/18

April 2018—The National Institute on Drug Abuse estimates that 100 million Americans suffer from chronic pain. The majority of drug overdose deaths involve an opioid, and nearly half of drug overdoses caused by opioids involve prescription drugs. The American Medical Association has formed a task force to combat the opioid crisis and has supported state-based prescription drug monitoring programs through which registered physicians can access information about their patients’ current medications before prescribing a new one.

Clinical Pathology Abstracts, 4/18

April 2018—Potential contributors to error in oxygen saturation calculation using a POC assay: Oxygen saturation is important for measuring respiratory status and calculating cardiac output for patients. The gold standard for oxygen saturation (sO2) is CO-oximetry, but other methods, which involve calculations rather than measurement of sO2, are widely used because they enable point-of-care (POC) testing. The calculations use mathematical models based on average physiologic parameters to relate blood parameters, such as pH, pCO2, and pO2, to sO2.

Anatomic Pathology Abstracts, 4/18

April 2018—Confirmation of ProMisE: a clinical classifier for endometrial cancer: Classification of endometrial carcinomas by morphologic features is irreproducible and imperfectly reflects tumor biology. The authors developed the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular classification system, based on The Cancer Genome Atlas genomic subgroups, and sought to confirm its feasibility and prognostic ability in a new, large cohort of endometrial carcinomas (ECs).